Arena Investors: Moment of Truth

Arena Pharmaceuticals investors, it has been a wild ride. Shares may be down 15% today from profit taking, but this stock is still a six-bagger year to date. However, June 27 looms large, as investors could be handsomely rewarded or left picking up the pieces. Find out why, and what health care editor David Williamson is urging investors to do.

A better approach
Health care investors are always looking for the next big breakthrough, and Motley Fool co-founder David Gardner recently identified a small-cap health care company poised for monster returns. To uncover this top pick today, enjoy the special free report: "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.

David Williamson holds no position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.


Read/Post Comments (10) | Recommend This Article (13)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 22, 2012, at 11:37 AM, Paulson545 wrote:

    The general feeling on the street is that ARNA will get approval....JMHO

  • Report this Comment On June 22, 2012, at 11:55 AM, mschmalf wrote:

    So this entire "article" is no more than a shill for a newsletter?

  • Report this Comment On June 22, 2012, at 12:12 PM, TMFGreenwave wrote:

    Apologies if the formatting is confusing, the brief article is a lead in for the video content discussing the obesity drug makers and Arena's upcoming approval. The special free report, which is not a newsletter, is a seperate offer.

    Best,

    David

  • Report this Comment On June 22, 2012, at 12:31 PM, WCoastGuynCA wrote:

    Mannkind is the most undervalued stock in the drug sector. The company is currently engaged in talks with multiple potential partners for its diabetes drug, Afreeza. It also has several promising drugs for the treatment of various cancers in development and has already partnered on one of them.

    Recent comments by management indicate that the company will obtain non-dilutive financing from a loan rather than through the sale of additional shares of stock which is one thing that has been holding the share price down.

    At under $2.05 a share there is substantial upside from here.

  • Report this Comment On June 22, 2012, at 1:41 PM, danico22 wrote:

    CTIC will go down to 0.01 .CEO Blanco is the worst CEO of all times and all companies.CTIC is burning millions a month since years ago and has NOT a single product on any market!

  • Report this Comment On June 22, 2012, at 5:02 PM, oracleatdelphi66 wrote:

    Fool needs to correct itself. Cell Therapeutics

    won approval for its drug Pixuvri in the EU in May.

  • Report this Comment On June 22, 2012, at 6:45 PM, bobleelaw wrote:

    CTIC

    "As of December 31, 2011,

    it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors.

    Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy

    for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy

    with paclitaxel and carboplatin. On May 31, 2012, CTI completed its acquisition gaining worldwide rights to

    S*BIO Pte Ltd.'s (S*BIO) pacritinib."

    I am long now on CTIC, we will see....

    Also holding my position on Arena Pharmaceuticals, it may tank, but without risk at times your return is limited.

    Just my 2 cents....

  • Report this Comment On June 23, 2012, at 8:42 AM, Allencarp wrote:

    If ARNA is trading around $11-13 a share on Wednesday and they are approved, what do you think their stock will jump to?

  • Report this Comment On June 23, 2012, at 4:14 PM, bobleelaw wrote:

    IMHO

    I don't see it at 11-13 due to the mass move to options on it, but I took stake low (2.27), so if all works out with the FDA I hope to see 13-15 on the price after a possible jump to 15-20 very short term.

    My plan is to sell 50% during spike, and hang on to the rest for the long haul.

    Or, I will be selling it all with my stop loss, and hope I still come out a bit ahead.

  • Report this Comment On June 25, 2012, at 12:22 PM, mschmalf wrote:

    My opologies to TMFGreenwave. It appears the first time I viewed the article either something blocked the video from my end or it temporarily had a broken link. It is working now.

    Thanks

Add your comment.

DocumentId: 1921399, ~/Articles/ArticleHandler.aspx, 4/24/2014 2:08:21 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement